
Andreas E Kulozik

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8116110/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	DNA methylation-based classification of central nervous system tumours. Nature, 2018, 555, 469-474.	27.8	1,872
2	Hotspot Mutations in H3F3A and IDH1 Define Distinct Epigenetic and Biological Subgroups of Glioblastoma. Cancer Cell, 2012, 22, 425-437.	16.8	1,551
3	The landscape of genomic alterations across childhood cancers. Nature, 2018, 555, 321-327.	27.8	1,068
4	Molecular Classification of Ependymal Tumors across All CNS Compartments, Histopathological Grades, and Age Groups. Cancer Cell, 2015, 27, 728-743.	16.8	933
5	A Perfect Message. Cell, 1999, 96, 307-310.	28.9	789
6	Genome Sequencing of SHH Medulloblastoma Predicts Genotype-Related Response to Smoothened Inhibition. Cancer Cell, 2014, 25, 393-405.	16.8	627
7	Nonsense-mediated decay approaches the clinic. Nature Genetics, 2004, 36, 801-808.	21.4	546
8	Enhancer hijacking activates GFI1 family oncogenes in medulloblastoma. Nature, 2014, 511, 428-434.	27.8	520
9	Atypical Teratoid/Rhabdoid Tumors Are Comprised of Three Epigenetic Subgroups with Distinct Enhancer Landscapes. Cancer Cell, 2016, 29, 379-393.	16.8	438
10	Gain-of-function mutations in <i>interleukin-7 receptor-α</i> (<i>IL7R</i>) in childhood acute lymphoblastic leukemias. Journal of Experimental Medicine, 2011, 208, 901-908.	8.5	307
11	Exon-Junction Complex Components Specify Distinct Routes of Nonsense-Mediated mRNA Decay with Differential Cofactor Requirements. Molecular Cell, 2005, 20, 65-75.	9.7	277
12	Outcome Prediction in Pediatric Medulloblastoma Based on DNA Copy-Number Aberrations of Chromosomes 6q and 17q and the <i>MYC</i> and <i>MYCN</i> Loci. Journal of Clinical Oncology, 2009, 27, 1627-1636.	1.6	274
13	Interactions between UPF1, eRFs, PABP and the exon junction complex suggest an integrated model for mammalian NMD pathways. EMBO Journal, 2008, 27, 736-747.	7.8	269
14	Activating NOTCH1 mutations predict favorable early treatment response and long-term outcome in childhood precursor T-cell lymphoblastic leukemia. Blood, 2006, 108, 1151-1157.	1.4	262
15	Next-generation personalised medicine for high-risk paediatric cancer patients – The INFORM pilot study. European Journal of Cancer, 2016, 65, 91-101.	2.8	262
16	Y14 and hUpf3b Form an NMD-Activating Complex. Molecular Cell, 2003, 11, 939-949.	9.7	258
17	Nonsense-mediated mRNA decay affects nonsense transcript levels and governs response of cystic fibrosis patients to gentamicin. Journal of Clinical Investigation, 2007, 117, 683-692.	8.2	252
18	Increased efficiency of mRNA 3′ end formation: a new genetic mechanism contributing to hereditary thrombophilia. Nature Genetics, 2001, 28, 389-392.	21.4	247

#	Article	IF	CITATIONS
19	Exome sequencing of osteosarcoma reveals mutation signatures reminiscent of BRCA deficiency. Nature Communications, 2015, 6, 8940.	12.8	242
20	Sarcoma classification by DNA methylation profiling. Nature Communications, 2021, 12, 498.	12.8	237
21	Oncogenic FAM131B–BRAF fusion resulting from 7q34 deletion comprises an alternative mechanism of MAPK pathway activation in pilocytic astrocytoma. Acta Neuropathologica, 2011, 121, 763-774.	7.7	211
22	Dexamethasone vs prednisone in induction treatment of pediatric ALL: results of the randomized trial AIEOP-BFM ALL 2000. Blood, 2016, 127, 2101-2112.	1.4	208
23	Childhood cancer predisposition syndromes—A concise review and recommendations by the Cancer Predisposition Working Group of the Society for Pediatric Oncology and Hematology. American Journal of Medical Genetics, Part A, 2017, 173, 1017-1037.	1.2	200
24	Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia. Blood, 2017, 129, e26-e37.	1.4	195
25	NMD: RNA biology meets human genetic medicine. Biochemical Journal, 2010, 430, 365-377.	3.7	192
26	Disassembly of Exon Junction Complexes by PYM. Cell, 2009, 137, 536-548.	28.9	162
27	Unusual bipartite mode of interaction between the nonsense-mediated decay factors, UPF1 and UPF2. EMBO Journal, 2009, 28, 2293-2306.	7.8	126
28	Mechanism of escape from nonsense-mediated mRNA decay of human β-globin transcripts with nonsense mutations in the first exon. Rna, 2011, 17, 843-854.	3.5	120
29	The Hierarchy of Exon-Junction Complex Assembly by the Spliceosome Explains Key Features of Mammalian Nonsense-Mediated mRNA Decay. PLoS Biology, 2009, 7, e1000120.	5.6	114
30	The activating STAT5B N642H mutation is a common abnormality in pediatric T-cell acute lymphoblastic leukemia and confers a higher risk of relapse. Haematologica, 2014, 99, e188-e192.	3.5	114
31	Functions of hUpf3a and hUpf3b in nonsense-mediated mRNA decay and translation. Rna, 2006, 12, 1015-1022.	3.5	112
32	The Pediatric Precision Oncology INFORM Registry: Clinical Outcome and Benefit for Patients with Very High-Evidence Targets. Cancer Discovery, 2021, 11, 2764-2779.	9.4	110
33	The abundance of RNPS1, a protein component of the exon junction complex, can determine the variability in efficiency of the Nonsense Mediated Decay pathway. Nucleic Acids Research, 2007, 35, 4542-4551.	14.5	107
34	High-resolution genomic profiling of childhood T-ALL reveals frequent copy-number alterations affecting the TGF-1 ² and PI3K-AKT pathways and deletions at 6q15-16.1 as a genomic marker for unfavorable early treatment response. Blood, 2009, 114, 1053-1062.	1.4	105
35	The efficiency of nonsense-mediated mRNA decay is an inherent character and varies among different cells. European Journal of Human Genetics, 2007, 15, 1156-1162.	2.8	102
36	Dual function of UPF3B in early and late translation termination. EMBO Journal, 2017, 36, 2968-2986.	7.8	89

#	Article	IF	CITATIONS
37	Enhancement of Radiation Response in Osteosarcoma and Rhabomyosarcoma Cell Lines by Histone Deacetylase Inhibition. International Journal of Radiation Oncology Biology Physics, 2010, 78, 237-245.	0.8	87
38	Front-line imatinib treatment in children and adolescents with chronic myeloid leukemia: results from a phase III trial. Leukemia, 2018, 32, 1657-1669.	7.2	86
39	Unexpected roles for UPF1 in HIV-1 RNA metabolism and translation. Rna, 2008, 14, 914-927.	3.5	83
40	NOTCH1 activation clinically antagonizes the unfavorable effect of PTEN inactivation in BFM-treated children with precursor T-cell acute lymphoblastic leukemia. Haematologica, 2013, 98, 928-936.	3.5	81
41	The German National Registry of Primary Immunodeficiencies (2012–2017). Frontiers in Immunology, 2019, 10, 1272.	4.8	71
42	p38 MAPK Controls Prothrombin Expression by Regulated RNA 3′ End Processing. Molecular Cell, 2011, 41, 298-310.	9.7	70
43	Pediatric T-cell lymphoblastic leukemia evolves into relapse by clonal selection, acquisition of mutations and promoter hypomethylation. Haematologica, 2015, 100, 1442-1450.	3.5	65
44	Exon Junction Complexes Show a Distributional Bias toward Alternatively Spliced mRNAs and against mRNAs Coding for Ribosomal Proteins. Cell Reports, 2016, 16, 1588-1603.	6.4	65
45	Comprehensive Analysis of Chromatin States in Atypical Teratoid/Rhabdoid Tumor Identifies Diverging Roles for SWI/SNF and Polycomb in Gene Regulation. Cancer Cell, 2019, 35, 95-110.e8.	16.8	65
46	Bridging to transplant with azacitidine in juvenile myelomonocytic leukemia: a retrospective analysis of the EWOG-MDS study group. Blood, 2015, 125, 2311-2313.	1.4	60
47	Single-cell analysis of structural variations and complex rearrangements with tri-channel processing. Nature Biotechnology, 2020, 38, 343-354.	17.5	59
48	Non-randomized therapy trial to determine the safety and efficacy of heavy ion radiotherapy in patients with non-resectable osteosarcoma. BMC Cancer, 2010, 10, 96.	2.6	56
49	Recommendations for diagnosis and treatment of methemoglobinemia. American Journal of Hematology, 2021, 96, 1666-1678.	4.1	56
50	A chemiluminescence-based reporter system to monitor nonsense-mediated mRNA decay. Biochemical and Biophysical Research Communications, 2006, 349, 186-191.	2.1	55
51	Genotyping circulating tumor DNA of pediatric Hodgkin lymphoma. Leukemia, 2020, 34, 151-166.	7.2	53
52	HIV-1 Recruits UPF1 but Excludes UPF2 to Promote Nucleocytoplasmic Export of the Genomic RNA. Biomolecules, 2015, 5, 2808-2839.	4.0	52
53	5â€azacytidine inhibits nonsenseâ€mediated decay in a <scp>MYC</scp> â€dependent fashion. EMBO Molecular Medicine, 2014, 6, 1593-1609.	6.9	51
54	A network of SMG-8, SMG-9 and SMG-1 C-terminal insertion domain regulates UPF1 substrate recruitment and phosphorylation. Nucleic Acids Research, 2015, 43, 7600-7611.	14.5	51

#	Article	IF	CITATIONS
55	Histone 3.3 hotspot mutations in conventional osteosarcomas: a comprehensive clinical and molecular characterization of six H3F3A mutated cases. Clinical Sarcoma Research, 2017, 7, 9.	2.3	51
56	Novel activating mutations lacking cysteine in type I cytokine receptors in acute lymphoblastic leukemia. Blood, 2014, 124, 106-110.	1.4	50
57	Genome-wide association study identifies multiple new loci associated with Ewing sarcoma susceptibility. Nature Communications, 2018, 9, 3184.	12.8	50
58	Cooperative Enhancer Activation by TLX1 and STAT5 Drives Development of NUP214-ABL1/TLX1-Positive T Cell Acute Lymphoblastic Leukemia. Cancer Cell, 2018, 34, 271-285.e7.	16.8	48
59	2,6-Diaminopurine as a highly potent corrector of UGA nonsense mutations. Nature Communications, 2020, 11, 1509.	12.8	46
60	Treatment of pediatric patients and young adults with particle therapy at the Heidelberg Ion Therapy Center (HIT): establishment of workflow and initial clinical data. Radiation Oncology, 2012, 7, 170.	2.7	44
61	Bone marrow failure unresponsive to bone marrow transplant is caused by mutations in thrombopoietin. Blood, 2017, 130, 875-880.	1.4	42
62	Daratumumab eradicates minimal residual disease in a preclinical model of pediatric T-cell acute lymphoblastic leukemia. Blood, 2019, 134, 713-716.	1.4	42
63	The uORF-containing thrombopoietin mRNA escapes nonsense-mediated decay (NMD). Nucleic Acids Research, 2006, 34, 2355-2363.	14.5	41
64	Plasticity of nuclear and cytoplasmic stress responses of RNA-binding proteins. Nucleic Acids Research, 2020, 48, 4725-4740.	14.5	40
65	Comparison of different IRT-PAP protocols to screen newborns for cystic fibrosis in three central European populations. Journal of Cystic Fibrosis, 2014, 13, 15-23.	0.7	39
66	<scp>PDX</scp> models recapitulate the genetic and epigenetic landscape of pediatric Tâ€cell leukemia. EMBO Molecular Medicine, 2018, 10, .	6.9	38
67	The differential expression of alternatively polyadenylated transcripts is a common stress-induced response mechanism that modulates mammalian mRNA expression in a quantitative and qualitative fashion. Rna, 2016, 22, 1441-1453.	3.5	36
68	<i>PTEN</i> abnormalities predict poor outcome in children with Tâ€cell acute lymphoblastic leukemia treated according to ALL ICâ€BFM protocols. American Journal of Hematology, 2019, 94, E93-E96.	4.1	36
69	Establishment of a patient-derived orthotopic osteosarcoma mouse model. Journal of Translational Medicine, 2015, 13, 136.	4.4	35
70	Treatment of neuroblastoma-related opsoclonus–myoclonus–ataxia syndrome with high-dose dexamethasone pulses. Pediatric Blood and Cancer, 2008, 50, 683-687.	1.5	34
71	Long-term outcome after polychemotherapy and intensive local radiation therapy of high-grade osteosarcoma. European Journal of Cancer, 2009, 45, 2447-2451.	2.8	34
72	Improved binding site assignment by high-resolution mapping of RNA–protein interactions using iCLIP. Nature Communications, 2015, 6, 7921.	12.8	32

#	Article	IF	CITATIONS
73	Therapy with lowâ€dose azacitidine for <scp>MDS</scp> in children and young adults: a retrospective analysis of the <scp>EWOG</scp> â€ <scp>MDS</scp> study group. British Journal of Haematology, 2016, 172, 930-936.	2.5	31
74	MYCN and HDAC5 transcriptionally repress <i>CD9</i> to trigger invasion and metastasis in neuroblastoma. Oncotarget, 2016, 7, 66344-66359.	1.8	30
75	Significant prevalence of sickle cell disease in Southwest Germany: results from a birth cohort study indicate the necessity for newborn screening. Annals of Hematology, 2016, 95, 397-402.	1.8	29
76	Proteomic Analysis Reveals Branch-specific Regulation of the Unfolded Protein Response by Nonsense-mediated mRNA Decay. Molecular and Cellular Proteomics, 2016, 15, 1584-1597.	3.8	28
77	The epidemiology of sickle cell disease in Germany following recent large-scale immigration. Pediatric Blood and Cancer, 2017, 64, e26550.	1.5	28
78	Downregulation of Notch signaling by Î ³ -secretase inhibition can abrogate chemotherapy-induced apoptosis in T-ALL cell lines. Annals of Hematology, 2009, 88, 613-621.	1.8	27
79	In vivo efficacy of the histone deacetylase inhibitor suberoylanilide hydroxamic acid in combination with radiotherapy in a malignant rhabdoid tumor mouse model. Radiation Oncology, 2012, 7, 52.	2.7	27
80	Treatment of patients with relapsed or refractory CD19+ lymphoid disease with T lymphocytes transduced by RV-SFG.CD19.CD28.4-1BBzeta retroviral vector: a unicentre phase I/II clinical trial protocol. BMJ Open, 2019, 9, e026644.	1.9	27
81	Low-dose Actinomycin-D treatment re-establishes the tumoursuppressive function of P53 in RELA-positive ependymoma. Oncotarget, 2016, 7, 61860-61873.	1.8	27
82	<i>CRLF2</i> over-expression is a poor prognostic marker in children with high risk T-cell acute lymphoblastic leukemia. Oncotarget, 2016, 7, 59260-59272.	1.8	24
83	Reversible central pontine and extrapontine myelinolysis in a 16-year-old girl. Child's Nervous System, 2001, 17, 294-296.	1.1	23
84	NMD inhibition by 5-azacytidine augments presentation of immunogenic frameshift-derived neoepitopes. IScience, 2021, 24, 102389.	4.1	22
85	Combining daratumumab with CD47 blockade prolongs survival in preclinical models of pediatric T-ALL. Blood, 2022, 140, 45-57.	1.4	22
86	The role of combined ion-beam radiotherapy (CIBRT) with protons and carbon ions in a multimodal treatment strategy of inoperable osteosarcoma. Radiotherapy and Oncology, 2021, 159, 8-16.	0.6	21
87	Aging of Preleukemic Thymocytes Drives CpG Island Hypermethylation in T-cell Acute Lymphoblastic Leukemia. Blood Cancer Discovery, 2020, 1, 274-289.	5.0	21
88	Newborn screening for severe combined immunodeficiency using a novel and simplified method to measure T-cell excision circles (TREC). Clinical Immunology, 2017, 175, 51-55.	3.2	20
89	Sickle cell disease in Germany: Results from a national registry. Pediatric Blood and Cancer, 2020, 67, e28130.	1.5	20
90	Internal ribosome entry sequenceâ€mediated translation initiation triggers nonsenseâ€mediated decay. EMBO Reports, 2006, 7, 722-726.	4.5	19

#	Article	IF	CITATIONS
91	High expression of miR-125b-2 and SNORD116 noncoding RNA clusters characterize ERG-related B cell precursor acute lymphoblastic leukemia. Oncotarget, 2017, 8, 42398-42413.	1.8	19
92	The thrombopoietin receptor P106L mutation functionally separates receptor signaling activity from thrombopoietin homeostasis. Blood, 2015, 125, 1159-1169.	1.4	18
93	Mutating heme oxygenase-1 into a peroxidase causes a defect in bilirubin synthesis associated with microcytic anemia and severe hyperinflammation. Haematologica, 2016, 101, e436-e439.	3.5	18
94	Gene Therapy of the Hemoglobinopathies. HemaSphere, 2020, 4, e479.	2.7	18
95	Prexasertib (LY2606368) reduces clonogenic survival by inducing apoptosis in primary patientâ€derived osteosarcoma cells and synergizes with cisplatin and talazoparib. International Journal of Cancer, 2020, 147, 1059-1070.	5.1	17
96	Expression of CD56 defines a distinct subgroup in childhood Tâ€ALL with inferior outcome. Results of the ALLâ€BFM 2000 trial. British Journal of Haematology, 2018, 183, 96-103.	2.5	16
97	Combination of suberoylanilide hydroxamic acid with heavy ion therapy shows promising effects in infantile sarcoma cell lines. Radiation Oncology, 2011, 6, 119.	2.7	14
98	Histone deacetylase inhibition sensitizes osteosarcoma to heavy ion radiotherapy. Radiation Oncology, 2015, 10, 146.	2.7	14
99	Pediatric Targeted Therapy: Clinical Feasibility of Personalized Diagnostics in Children with Relapsed and Progressive Tumors. Brain Pathology, 2016, 26, 506-516.	4.1	14
100	Chromatin accessibility landscape of pediatric T″ymphoblastic leukemia and human Tâ€cell precursors. EMBO Molecular Medicine, 2020, 12, e12104.	6.9	13
101	Blasticidin S inhibits mammalian translation and enhances production of protein encoded by nonsense mRNA. Nucleic Acids Research, 2021, 49, 7665-7679.	14.5	13
102	Hereditary thrombocythemia caused by a thrombopoietin (THPO) gain-of-function mutation associated with multiple myeloma and congenital limb defects. Annals of Hematology, 2012, 91, 1129-1133.	1.8	11
103	MAP3K7 is recurrently deleted in pediatric T-lymphoblastic leukemia and affects cell proliferation independently of NF-I®B. BMC Cancer, 2018, 18, 663.	2.6	11
104	Long-term remission of children with relapsed and secondary anaplastic large cell non-Hodgkin lymphoma (ALCL) following treatment with pulsed dexamethasone and low dose etoposide. Pediatric Blood and Cancer, 2008, 50, 126-129.	1.5	10
105	Haemoglobin Variant Screening in Jamaica: Meeting Student's Request. British Journal of Haematology, 2016, 172, 634-636.	2.5	10
106	Stay Tuned: miRNA Expression and Nonsense-Mediated Decay in Brain Development. Molecular Cell, 2011, 42, 407-408.	9.7	9
107	A 15q24 microdeletion in transient myeloproliferative disease (<scp>TMD</scp>) and acute megakaryoblastic leukaemia (<scp>AMKL</scp>) implicates <scp>PML</scp> and <scp>SUMO</scp> 3 in the leukaemogenesis of <scp>TMD</scp> / <scp>AMKL</scp> . British Journal of Haematology, 2012, 157, 1801	2.5	9
108	180-187. Constitutional PIGA mutations cause a novel subtype of hemochromatosis in patients with neurologic dysfunction. Blood, 2022, 139, 1418-1422.	1.4	8

#	Article	IF	CITATIONS
109	Protocol II vs protocol III given twice during reinduction therapy in children with medium-risk ALL. Blood, 2017, 130, 2146-2149.	1.4	7
110	Germline RET variants underlie a subset of paediatric osteosarcoma. Journal of Medical Genetics, 2021, 58, 20-24.	3.2	7
111	NOTCH1 mutation, TP53 alteration and myeloid antigen expression predict outcome heterogeneity in children with first relapse of T-cell acute lymphoblastic leukemia. Haematologica, 2017, 102, e249-e252.	3.5	6
112	(Phospho)proteomic Profiling of Microsatellite Unstable CRC Cells Reveals Alterations in Nuclear Signaling and Cholesterol Metabolism Caused by Frameshift Mutation of NMD Regulator UPF3A. International Journal of Molecular Sciences, 2020, 21, 5234.	4.1	6
113	Low-frequency variation near common germline susceptibility loci are associated with risk of Ewing sarcoma. PLoS ONE, 2020, 15, e0237792.	2.5	6
114	Genetic modifiers of fetal hemoglobin affect the course of sickle cell disease in patients treated with hydroxyurea. Haematologica, 2022, 107, 1577-1588.	3.5	6
115	Haematological malignancies following temozolomide treatment for paediatric high-grade glioma. European Journal of Cancer, 2017, 81, 1-8.	2.8	4
116	Introduction of Universal Newborn Screening for Sickle Cell Disease in Germany—A Brief Narrative Review. International Journal of Neonatal Screening, 2021, 7, 7.	3.2	4
117	Pediatric T-ALL type-1 and type-2 relapses develop along distinct pathways of clonal evolution. Leukemia, 2022, 36, 1759-1768.	7.2	4
118	β-Thalassemia Mutations in Jamaica: Geographic Variation in Small Communities. Hemoglobin, 2018, 42, 294-296.	0.8	3
119	Intracardiac Extension of Wilms Tumor: A Case of a 2.5-Year-Old Girl Presenting with Upper Venous Congestion Caused by Tumor Growth into the Right Cardiac Ventricle. Case Reports in Oncology, 2019, 12, 33-38.	0.7	3
120	Benefits of a Disease Management Program for Sickle Cell Disease in Germany 2011–2019: The Increased Use of Hydroxyurea Correlates with a Reduced Frequency of Acute Chest Syndrome. Journal of Clinical Medicine, 2021, 10, 4543.	2.4	3
121	Reply to J.C. Lindsey et al. Journal of Clinical Oncology, 2011, 29, e348-e349.	1.6	2
122	Differential Analysis of the Nuclear and the Cytoplasmic RNA Interactomes in Living Cells. Methods in Molecular Biology, 2022, 2428, 291-304.	0.9	2
123	Mpl Gain-of-Function Mutations Can be Classified By Differential Subcellular Processing, Molecular Mechanisms, Mode of Inheritance and Clinical Impact. Blood, 2015, 126, 1634-1634.	1.4	1
124	The INFORM personalized medicine study for high-risk pediatric cancer patients Journal of Clinical Oncology, 2017, 35, 10509-10509.	1.6	1
125	Odisha Revisited: A Personal Account. Frontiers in Medicine, 2021, 8, 745337.	2.6	1
126	Summary of Joint European Hematology Association (EHA) and EuroBloodNet Recommendations on Diagnosis and Treatment of Methemoglobinemia. HemaSphere, 2021, 5, e660.	2.7	1

Andreas E Kulozik

#	Article	IF	CITATIONS
127	The role of nonsense-mediated decay in physiological and pathological processes. , 2005, , .		0
128	The best of 25 years: mRNA 3′end processing. Rna, 2015, 21, 640-641.	3.5	0
129	The Prothrombin C>T Mutation at Position 20209 (F2 20209*T) Promotes 3′end mRNA Processing and Thus Contributes to Thrombophilia through Gain-of-Function Blood, 2005, 106, 2145-2145.	1.4	0
130	The Early Treatment Response of the Clinically Challenging Group of Childhood T-ALL without NOTCH1 Mutations Is Signified by a Specific mRNA Gene Profile Blood, 2007, 110, 2789-2789.	1.4	0
131	Whole Exome Sequencing Identifies Novel Lyst-Missense Mutations In Incomplete Childhood Chediak-Higashi-Syndrome Presenting As Hemphagocytic Lymphohistiocytosis (HLH). Blood, 2013, 122, 3479-3479.	1.4	0
132	Gene Panel Sequencing of Primary and Relapsed Pediatric T-ALL Shows That Relapse-Specific Mutations Are Diverse and Mostly Non-Recurrent. Blood, 2015, 126, 1428-1428.	1.4	0
133	Does the world need germline editing for ß-thalassemia?. Haematologica, 2021, , .	3.5	0
134	TP53 and KRAS Variants at Initial Diagnosis Identify an Ultra-High Risk Group of Pediatric T-Lymphoblastic Leukemia (T-ALL). Blood, 2021, 138, 1315-1315.	1.4	0
135	Co-Targeting of CD38 and CD47 in T Cell Acute Lymphoblastic Leukemia. Blood, 2020, 136, 39-40.	1.4	0
136	Title is missing!. , 2020, 15, e0237792.		0
137	Title is missing!. , 2020, 15, e0237792.		0
138	Title is missing!. , 2020, 15, e0237792.		0
139	Title is missing!. , 2020, 15, e0237792.		Ο